6 mg of tirzepatide Flex-Dose 1 mL Injectable 10 mg/mL Tirzepatide (60mg) - theragenetics

Most discussion of semaglutide and tirzepatide in our specialty still centers on weight reduction

J Psychosom Res 1985;29:71-83

Early evidence suggests substantial weight loss potential in clinical trials

However, in March 2024, Semaglutide has also been demonstrated to reduce the cardiovascular death opportunity, non-fatal myocardial infarction, or nonfatal stroke risk in diabetic mellitus type II patients who are at high cardiovascular risk by 20 percent

Taking GLP-1 agonists without behavior and lifestyle modification can actually lead to worse metabolic health due to both a loss of muscle mass and nutrient deficiencies

requires screening and monitoring Tirzepatide (GLP-1/GIP medication) What it is: Prescription GLP-1/GIP medication Primary effect: Appetite regulation and satiety Evidence for weight loss: Strong What to know: FDA-approved options exist for chronic weight management